Compare F.N.B. Corporation Common Stock (FNB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while Recursion Pharmaceuticals Inc trades at $3.65 (market cap $2.02B). The key difference: F.N.B. Corporation Common Stock is far larger — about 3× Recursion Pharmaceuticals Inc's market cap, and F.N.B. Corporation Common Stock pays a 3.07% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FNB | RXRX | |
|---|---|---|
Market Cap | $6.03B | $2.02B |
Volume | 7,117,178 | 18,610,436 |
Sector | Financials | Health |
52-Week High | $19.49 | $6.79 |
52-Week Low | $14.65 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $10.52B | $1.54B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after beating expectations in previous quarters. Financials show significant losses with -961.97% net income margin and $644.76M net loss in 2025, though revenue grew to $74.26M. Recent strategic partnerships with Tempus and Roche highlight AI-driven drug discovery focus.
Outlook remains speculative with high-risk/high-reward profile. The AI drug discovery platform shows promise through partnerships, but profitability challenges and cash burn require careful monitoring. Analyst consensus leans cautious with 40% buy ratings amid substantial operational losses. Key catalysts include pipeline advancements and partnership milestones through 2028.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
